Clinical outcomes at 1 year following transcatheter aortic valve replacement

Importance: Introducing new medical devices into routine practice raises concerns because patients and outcomesmay differ from those in randomized trials. Objective: To update the previous report of 30-day outcomes and present 1-year outcomes following transcatheter aortic valve replacement (TAVR) in the United States. Design, Setting, and Participants: Data from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies Registry were linked with patient-specific Centers for Medicare & Medicaid Services (CMS) administrative claims data. At 299 US hospitals, 12 182 patients linked with CMS data underwent TAVR procedures performed from November 2011 through June 30, 2013, and the end of the follow-up period was June 30, 2014. Exposure: Transcatheter aortic valve replacement. Main Outcomes and Measures: One-year outcomes including mortality, stroke, and rehospitalization were evaluated using multivariate modeling. Results: The median age of patients was 84 years and 52%were women, with a median STS Predicted Risk of Operative Mortality (STS PROM) score of 7.1%. Following the TAVR procedure, 59.8%were discharged to home and the 30-day mortality was 7.0% (95%CI, 6.5%-7.4%) (n = 847 deaths). In the first year after TAVR, patients were alive and out of the hospital for a median of 353 days (interquartile range, 312-359 days); 24.4%(n = 2074) of survivors were rehospitalized once and 12.5%(n = 1525) were rehospitalized twice. By 1 year, the overall mortality rate was 23.7%(95%CI, 22.8%-24.5%) (n = 2450 deaths), the stroke rate was 4.1%(95%CI, 3.7%-4.5%) (n = 455 stroke events), and the rate of the composite outcome of mortality and stroke was 26.0%(25.1%-26.8%) (n = 2719 events). Characteristics significantly associated with 1-year mortality included advanced age (hazard ratio [HR] for ≥95 vs <75 years, 1.61 [95%CI, 1.24-2.09]; HR for 85-94 years vs <75 years, 1.35 [95%CI, 1.18-1.55]; and HR for 75-84 years vs <75 years, 1.23 [95%CI, 1.08-1.41]), male sex (HR, 1.21; 95%CI, 1.12-1.31), end-stage renal disease (HR, 1.66; 95%CI, 1.41-1.95), severe chronic obstructive pulmonary disease (HR, 1.39; 95%CI, 1.25-1.55), nontransfemoral access (HR, 1.37; 95%CI, 1.27-1.48), STS PROM score greater than 15%vs less than 8%(HR, 1.82; 95%CI, 1.60-2.06), and preoperative atrial fibrillation/flutter (HR, 1.37; 95%CI, 1.27-1.48). Compared with men, women had a higher risk of stroke (HR, 1.40; 95%CI, 1.15-1.71). Conclusions and Relevance: Among patients undergoing TAVR in US clinical practice, at 1-year follow-up, overall mortality was 23.7%, the stroke rate was 4.1%, and the rate of the composite outcome of death and stroke was 26.0%. These findings should be helpful in discussions with patients undergoing TAVR.